Sun Eyes Big Stage For Concert’s Alopecia Asset
Executive Summary
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.
You may also be interested in...
5 Talking Points As Sun's Cequa Hits Home Turf And There's Restasis
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
FDA Import Alert At Sun’s Site: Here’s The Long And Short Of The Impact
US FDA import alert at Halol site comes as a setback for Sun Pharma, but analysts shrug off wider concerns for now given the low dependence on the facility for future growth. Investors are, however, also tracking the escalated compliance situation for the firm’s Mohali plant, inherited via the Ranbaxy deal.